Substitute cost disadvantage ‘unjust’

Pharmacy body raises concerns that Actemra substitution issues will impact affordability and equity of access The PSA has raised concerns about the news that community pharmacists are now able to substitute tocilizumab (Actemra) formulations without prior prescriber approval due to serious shortages. Under the new Serious Scarcity Substitution Instrument (SSSI) for Actemra, the 162 mg/0.9